Case Report
Guillain–Barré Syndrome Associated with COVID-19 in a Japanese Male
Table 2
Demographics of previous and present cases of Guillain-Barré syndrome associated with COVID-19 in Japan.
| Case | Age | Sex | Clinical feature | GBS onset from the onset of COVID-19 | GBS onset from COVID-19 recovery | GBS electrophysiological subtype | Anti-ganglioside antibody | CSF protein (mg/dL) | Immunological treatment |
| Wada et al. [7] | 69 | Male | Absence of cough reflex, muscle weakness, areflexia | Not described | Not described | Not described | Anti-Gal-C antibody | 202 | IVIg | Hirayama et al. [5] | 54 | Female | Muscle weakness, numbness, and areflexia in the lower limb | 20 | Approximately 1 week | Axonal type | Negative | Normal level | No treatment | Kakumoto et al. [6] | 22 | Male | Muscle weakness, hypesthesia, dysarthria, dysphagia, left-sided facial numbness, and dysautonomia | 16 | 6 | AIDP | Negative | 307 | IVIg | Present case | 52 | Male | Muscle weakness, dysphagia, areflexia, hyperhidrosis | 10 | 1 | AIDP | Anti-GM3 antibody | 55 | IVIg, IVMP |
|
|
Abbreviations: GBS, Guillain–Barré syndrome; CSF, cerebrospinal fluid; AIDP, acute inflammatory demyelinating polyneuropathy; IVIg, intravenous immunoglobulin; IVMP, intravenous methylprednisolone.
|